PMDA Risk Communications (drug risk information of ongoing evaluation)

日本語ページはこちら

This webpage provides drug risk information which has come under review by the PMDA and the Ministry of Health, Labour and Welfare (MHLW). Information provided here is as follows:

Risk information suggested by a certain amount of accumulated information of adverse drug reactions (ADR) reports or Early Post-marketing Phase Vigilance (EPPV)
Safety measures such as revision of PRECAUTIONS in the package insert of the product might be taken after the ongoing review.
When evaluations are completed, the information in the table below will be deleted. You will find the results of evaluation on the “Revisions of PRECAUTIONS” webpage.
Risk information which has attracted the attention of foreign regulatory agencies or academic societies based on studies published in scientific journals, etc., for which the PMDA and MHLW have started their evaluation since the risk information is related to drugs marketed in Japan
Information provided here is still under review. If you are taking the following drugs, you should NOT stop taking them or reduce the dosage without consulting a physician. Consult your healthcare professionals if you have any questions or concerns about these drugs.

**Risk information**^note) **for which some safety measures might be taken**

Note) This English version of risk information is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA shall not be responsible for any consequences resulting from the use of this English version.
Date	Nonproprietary Name	Risk Information of Ongoing Evaluation	Related Information	Investigation Results
April 18, 2025	Acetazolamide Acetazolamide sodium Indapamide Mefruside Hydrochlorothiazide Benzylhydrochlorothiazide Trichlormethiazide Furosemide Torasemide Azosemide Candesartan cilexetil/ hydrochlorothiazide Telmisartan/hydrochlorothiazide Telmisartan/amlodipine besilate/hydrochlorothiazide Valsartan/hydrochlorothiazide Losartan potassium/ hydrochlorothiazide Irbesartan/trichlormethiazide	Acute myopia, angle closure glaucoma, choroidal effusion	－	－
	Eplerenone Voriconazole Posaconazole	Precautions for concomitant use of eplerenone with voriconazole or posaconazole	－	－
	Iodixanol	Cardiac arrest	－	－
	Nemolizumab (genetical recombination)	Pemphigoid	－	－
	Borofalan (¹⁰B)	Necrosis, mucosal ulceration, perforation, fistula	－	－
	Venetoclax Ceritinib	Precautions for concomitant use of venetoclax and ceritinib	－	－
December 26, 2013	Recombinant absorbed bivalent human papillomavirus-like particle vaccine Recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine	Symptoms related to pain	－	Summary of the Report on the Surveillance Results of HPV Vaccines [40.4 KB]

**Risk information which has attracted the attention of foreign regulatory agencies or academic societies, for which the PMDA and MHLW have started their evaluation**
Posted Date	Nonproprietary Name	Risk Information of Ongoing Evaluation	Related Information	Investigation Results
November 30, 2011	Bevacizumab (genetical recombination)	Japan's view on Avastin (bevacizumab) for breast cancer indication [54.3 KB]	Press Announcement from the FDA Review report of AVASTIN 100mg/4mL Intravenous Infusion and AVASTIN 400mg/16mL Intravenous Infusion on July 14, 2011 (only in Japanese) [1,708 KB]	－